Skip to main content
TipRanks
Go Ultimate75% OFF

Cosmo Bio Co., Ltd. (3386) AI Stock Analysis

0 Followers
JP:3386

Cosmo Bio Co., Ltd.

(TSE/TYO:3386)

Select Model
Rating:60Neutral
Price Target:JPY 1,289.00â–²(7.06% Upside)
Action:reiterated
Date:11/06/26

Cosmo Bio earns a moderate score. The dominant strength is an exceptionally conservative balance sheet with virtually no debt and consistently growing equity, backed by a recovery in operating and free cash flow. The key risk is sustained margin compression: operating profit and ROE have fallen sharply from 2021 peaks, and revenue growth alone has not restored profitability. Technicals are a drag, with the price below all major moving averages and a negative MACD pointing to a mild downtrend. Valuation provides some support, with a fair P/E of 18.9 and an attractive, well-covered 4.07% dividend yield that rewards patient income investors while the company works to stabilize margins.

Positive Factors
Very low leverageThe exceptionally conservative capital structure limits interest and refinancing pressure while preserving flexibility to fund operations, research-support capabilities, and growth initiatives. A strong equity base also improves resilience if industry demand weakens or investment requirements increase over the coming quarters.
Negative Factors
Profitability compressionThe substantial decline in operating profit and net income shows that revenue growth has not translated into comparable earnings power. Unless profitability recovers, weaker margins could constrain reinvestment, reduce the benefit of scale, and limit sustainable returns despite continued sales expansion.

Cosmo Bio Co., Ltd. (3386) vs. iShares MSCI Japan ETF (EWJ)

-20%-10%0%10%20%30%JP:3386-8.95%EWJ+11.03%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
JPY 6.89B
Dividend Yield
4.15%
Average Volume (3M)
4,153
Price to Earnings (P/E)
20.7
Beta (1Y)
0.29
Revenue Growth
7.17%
EPS Growth
36.23%
Country
Japan
Employees
182
Sector
Healthcare
Sector Strength
51
Industry
Medical - Diagnostics & Research

Cosmo Bio Co., Ltd. Business Overview & Revenue Model

Company Description

Cosmo Bio Company, Limited is a key player in the life science research sector, involved in the global import, export, manufacturing, marketing, and distribution of essential biotools. Their extensive product line includes biochemical reagents, speci...

Cosmo Bio Co., Ltd. Financial Statement Overview

Summary

Cosmo Bio's financial profile is anchored by a fortress balance sheet (score 78) with essentially no debt (debt/equity ~0.2%), steadily rising equity of ¥9.37 billion and growing total assets. This is offset by weak income statement trends (score 52): despite 4.4% revenue growth to ¥10.77 billion, gross margin has slipped from ~40% to ~34%, EBIT has collapsed from ¥1.05 billion in 2021 to ¥342 million, and ROE has fallen to ~3.6%. Cash flow (score 61) improved markedly, with operating cash flow rebounding to ¥595 million and free cash flow to ¥366 million, though history shows high volatility. Net: safety and liquidity are strong, but profitability and capital efficiency are deteriorating.

Income Statement

52Neutral

Balance Sheet

78Positive

Cash Flow

61Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue11.27B10.77B10.04B9.34B9.55B9.23B
Gross Profit3.89B3.70B3.33B3.25B3.44B3.66B
EBITDA515.00M509.00M455.00M801.00M931.00M1.26B
Net Income328.00M336.00M262.00M442.00M517.00M737.00M
Balance Sheet
Total Assets12.18B12.66B11.72B10.87B10.31B10.07B
Cash, Cash Equivalents and Short-Term Investments4.08B2.95B2.69B3.02B3.04B3.56B
Total Debt20.00M20.00M22.00M24.00M27.00M28.00M
Total Liabilities2.29B2.70B2.17B1.84B1.69B1.75B
Stockholders Equity9.30B9.37B8.97B8.45B8.05B7.79B
Cash Flow
Free Cash Flow0366.00M25.00M636.00M180.00M507.00M
Operating Cash Flow0595.00M241.00M736.00M284.00M648.00M
Investing Cash Flow043.00M-217.00M-758.00M-291.00M-145.00M
Financing Cash Flow0-283.00M-479.00M-201.00M-236.00M-420.00M

Cosmo Bio Co., Ltd. Technical Analysis

Technical Analysis SentimentNegative
Last Price1204.00

Price Trends

50DMA1240.44Negative
100DMA1244.33Negative
200DMA1250.41Negative

Market Momentum

MACD-8.26Positive
RSI34.76Neutral
STOCH23.32Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:3386, the sentiment is Negative. The current price of 1204.00 is below the 20-day moving average (MA) of 1223.60, below the 50-day MA of 1240.44, and below the 200-day MA of 1250.41, indicating a bearish trend. The MACD of -8.26 indicates Positive momentum. The RSI at 34.76 is Neutral, neither overbought nor oversold. The STOCH value of 23.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:3386.

Cosmo Bio Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

JP:3386 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
JP:4570JP:457070OutperformJPY 8.48B21.59―0.66%7.10%17.17%
JP:3386JP:338660NeutralJPY 6.97B20.70―4.15%7.17%36.23%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
JP:4978JP:497845NeutralJPY 11.75B-24.37――-8.23%-48.10%
JP:4892JP:489242NeutralJPY 5.08B-6.32――214.65%22.18%
JP:7776JP:777637UnderperformJPY 6.07B-4.74――-49.43%-3.77%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%150%JP:3386JP:4570JP:4892JP:4978JP:7776Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
JP:3386 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JP:3386Cosmo Bio Co., Ltd.1204.00-121.22-9.15%
JP:4570Immuno-Biological Laboratories Co., Ltd.910.00-502.94-35.60%
JP:4892Cyfuse Biomedical K.K.503.00-67.00-11.75%
JP:4978ReproCELL Inc.110.00-45.00-29.03%
JP:7776CellSeed Inc.153.00-141.00-47.96%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 05, 2026